CNBC Pro: Morgan Stanley says this global biotech stock could soar 398% in the next year
Analysts at Morgan Stanley think one global biotech company's stock could soar 398% in the next year. The company's latest regenerative medicine has completed phase 2 trials in Japan and U.S. and is awaiting final approval.
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut: